BAFNAPH Stock Overview
Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Bafna Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹86.00 |
| 52 Week High | ₹124.45 |
| 52 Week Low | ₹75.90 |
| Beta | 0.50 |
| 1 Month Change | 10.19% |
| 3 Month Change | -11.79% |
| 1 Year Change | 6.24% |
| 3 Year Change | -34.25% |
| 5 Year Change | n/a |
| Change since IPO | 1,769.57% |
Recent News & Updates
Recent updates
We Think Bafna Pharmaceuticals (NSE:BAFNAPH) Can Stay On Top Of Its Debt
Aug 15
Optimistic Investors Push Bafna Pharmaceuticals Limited (NSE:BAFNAPH) Shares Up 27% But Growth Is Lacking
Feb 13The Strong Earnings Posted By Bafna Pharmaceuticals (NSE:BAFNAPH) Are A Good Indication Of The Strength Of The Business
Nov 19Do Its Financials Have Any Role To Play In Driving Bafna Pharmaceuticals Limited's (NSE:BAFNAPH) Stock Up Recently?
Dec 10Shareholder Returns
| BAFNAPH | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -0.9% | 1.4% | 2.8% |
| 1Y | 6.2% | 57.2% | 46.6% |
Return vs Industry: BAFNAPH underperformed the Indian Pharmaceuticals industry which returned 57.2% over the past year.
Return vs Market: BAFNAPH underperformed the Indian Market which returned 46.6% over the past year.
Price Volatility
| BAFNAPH volatility | |
|---|---|
| BAFNAPH Average Weekly Movement | 4.5% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: BAFNAPH has not had significant price volatility in the past 3 months.
Volatility Over Time: BAFNAPH's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 588 | Bansilal Mahaveer Bafna | www.bafnapharma.com |
Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. The company provides delayed and sustained release, chewable, and orally disintegrating tablets. It also exports its products.
Bafna Pharmaceuticals Limited Fundamentals Summary
| BAFNAPH fundamental statistics | |
|---|---|
| Market cap | ₹2.03b |
| Earnings (TTM) | ₹112.64m |
| Revenue (TTM) | ₹1.53b |
18.1x
P/E Ratio1.3x
P/S RatioIs BAFNAPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BAFNAPH income statement (TTM) | |
|---|---|
| Revenue | ₹1.53b |
| Cost of Revenue | ₹1.07b |
| Gross Profit | ₹463.83m |
| Other Expenses | ₹351.19m |
| Earnings | ₹112.64m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 4.76 |
| Gross Margin | 30.25% |
| Net Profit Margin | 7.35% |
| Debt/Equity Ratio | 20.1% |
How did BAFNAPH perform over the long term?
See historical performance and comparison